Pfizer to show strongly at this year's ASCO

25 May 2023

US pharma giant Pfizer (NYSE: PFE) is to present data on more than 15 drugs - including six early pipeline assets - at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2 through June 6.

These data will be in more than 10 different cancer types, with the results including findings on three potential therapies with regulatory decisions anticipated this year in certain types of multiple myeloma, prostate cancer, and non-small cell lung cancer.

"New data across the four key areas of our industry-leading portfolio"Data on elranatamab in multiple myeloma, Talzenna (talazoparib) and Xtandi (enzalutamide) in prostate cancer and Braftovi (encorafenib) and Mektovi (binimetinib) in prostate cancer, is among the most eagerly anticipated.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK